SORAFENIB FOR OLDER PATIENTS WITH RENAL CELL CARCINOMA: SUBSET ANALYSIS FROM A RANDOMIZED TRIAL

Background. The perception that older cancer patients may be at higher risk than younger patients of toxic effects from cancer therapy but may obtain less clinical benefit from it may be based on the underrepresentation of older patients in clinical trials and the known toxic effects of cytotoxic chemotherapy. It is not known how older patients respond to targeted therapy.

Methods.  This retrospective subgroup analysis of data from the phase 3, randomized Treatment Approach in Renal Cancer Global Evaluation Trial examined the safety and efficacy of sorafenib in older (age ≥ 70 years, n = 115) and younger patients (age <70 years, n = 787) who received treatment for advanced renal cell carcinoma. Patient demographics and progression-free survival were recorded. Best tumor response, clinical benefit rate (defined as complete response plus partial response plus stable disease), time to self-reported health status deterioration, and toxic effects were assessed by descriptive statistics. Health-related quality of life was assessed with a Cox proportion- al hazards model. Kaplan - Meier analyses were used to summarize time-to-event data.

Results. Median progression-free survival was similar in sorafenib-treated younger patients (23.9 weeks; hazard ratio [HR] for progression compared with placebo = 0.55, 95% confidence interval [CI] = 0.47 to 0.66) and older patients (26.3 weeks; HR = 0.43, 95% CI = 0.26 to 0.69). Clinical benefit rates among younger and older sorafenib-treated patients were also similar (83.5% and 84.3%, respectively) and were superior to those of younger and older placebo-treated patients (53.8% and 62.2%, respectively). Adverse events were predictable and manageable regardless of age. Sorafenib treatment delayed the time to self-reported health status deterioration among both older patients (121 days with sorafenib vs 85 days with placebo; HR = 0.66, 95% CI = 0.43 to 1.03) and younger patients (90 days with sorafenib vs 52 days with placebo; HR = 0.69, 95% CI = 0.59 to 0.81) and improved quality of life over that time.

 Conclusions. Among patients with advanced renal cell carcinoma receiving sorafenib treatment, outcomes of older ( ≥ 70 years) and younger (<70 years) patients were similar.

1. Ahmad T., Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10(18): 6388—92.

2. Escudier B., Eisen T., Stadler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125—34 .

3. Therasse P., Arbuck S.G., Eisenhauer E.A. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205—16.

4. Cella D.F., Yount S., Du H. et al. Development and validation of the Functional Assessment of Cancer Therapy- Kidney Symptom Index (FKSI). J Support Oncol 2006;4(4):191—9.

5. Cella D.F., Tulsky D.S., Gray G. et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11(3):570—9.

6. Wilhelm S.M., Carter C., Tang L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progres- sion and angiogenesis. Cancer Res 2004;64(19):7099—109.

7. Pili R., Guo Y., Chang J. et al. Altered angiogenesis underlying age-dependent changes in tumor growth . J Natl Cancer Inst 1994;86(17):1303—14.

8. Kaptzan T., Skutelsky E., Itzhaki O. et al. Effi cacy of anti-angiogenic treatment of tumors in old versus young mice . Mech Ageing Dev 2006;127(4):398—409.

9. Atzpodien J., Wandert T., Reitz M. Age does not impair the effi cacy of immunochemotherapy in patients with metastatic renal carcinoma. Crit Rev Oncol Hematol 2005;55(3):193—9.

10. Schoffski P., Dumez H, Clement P. et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell can- cer: a review. Ann Oncol 2006;17(8): 1185—96.